GLP-1 Market
LLY $1354.00 ▼ -0.8% NVO $40.31 ▲ +0.0% PFE $29.39 ▼ -1.6% VKTX $26.84 ▲ +4.1% KLRA $12.97 ▲ +6.6% GPCR $20.35 ▲ +6.7% RHHBY $59.37 ▼ -0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Mexidol sequential therapy

Company
Research Center of Neurology, Russia
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 7, 2026

Trial details
  • Completed NCT NCT07700615

    Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults

    Not yet reported Pharmasoft 120 participants Est. completion 2025-11-05 4 sites Stand-alone
    Other conditions: Vascular Cognitive Impairment no Dementia
    View official trial listing →
  • Active, not recruiting NCT NCT07923240

    Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders

    Not yet reported Research Center of Neurology, Russia 30 participants Est. completion 2026-12-25 1 site Stand-alone
    Other conditions: Metabolic Abnormalities, Obesity & Overweight, Cerebral Atherosclerosis, Cerebrovascular Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.